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Treatment of Canine 
Osteosarcoma 
Each year about 10,000 dogs in the United 
States, mostly of the large and giant breeds, are 
diagnosed with osteosarcoma (OSA), a painful bone 
tumor. This disease also occurs in humans, though 
not in such high numbers. Osteosarcoma in dogs 
affects primarily the long bones of the leg, but can 
affect bones of the spine, skull, or ribs. 
"Over the last ten years there have been major 
advances in treatment of this disease in both 
species.'' said Dr. M. Joy Weinstein, assistant 
professor of surgery at Peon's School of Veterinary 
Medicine, ''but better treatment protocols are still 
needed. Therapy for osteosarcoma of long bones 
includes amputation with or without chemotherapy, 
or limb-sparing surgery and chemotherapy. Limb­
sparing surgery involves removal of the primary 
tumor while preserving the limb through use of a 
bone graft or a prosthesis. Two chemotherapy drugs 
that appear to be most effective in this disease are 
adriamycin and cisplatin. Unfortunately, at this 
point in time, we cannot cure the disease, but we can 
give the dog a good quality of life for a number of 
months or years." 
Dr. Weinstein, who returned to Penn after 
surgical specialty training at Tufts University School 
of Veterinary Medicine, is conducting a study 
assessing perioperative and postoperative treatment 
of OSA by administering adriamycin and cisplatin 
concurrently. ''These drugs usually are used alone or 
alter nated to reduce the growth of metastases. By 
administering them together we hope to achieve an. 
additive effect." 
Osteosarcoma in dogs frequently manifests itself 
as a limp; the dog is in pain and often refuses to use 
I he leg. Radiographs reveal a bone LUmor at the end 
of the long bone of the leg, either front or rear. 
'·When the animal comes to the veterinarian, the 
tumor has already spread through mkroscopic 
lesions to other parts of the body, primarily the 
lung," said Dr. Weinstein. "If we amputate rhe leg 
and give no other treatment, the median survival time 
is about 18 weeks, though some dogs (10 percent) live 
more than a year. Jf the animal is treated with 
chemotherapy, either cisplati n or adriamycin, the 
median survival time increases to about 40-45 weeks, 
with nearly 50% of the dogs living more than a 
year." 
Amputation of the affected limb is Dr. 
Weinstein's preferred surgical treatment. "It reli eves 
the pain and the dog can get around quite well on 
three legs," she explained. ''Most dogs walk one day 
after surgery and need exercise restrictions for only 
about LWO weeks." An alternative to amputation is 
limb sparing surgery. She recommends this treatment 
for dogs that would not get around well on three legs 
or those cases where an owner cannot accept 
amputation as an option for the dog. Here the tumor 
and the affected section of bone are removed� and a 
bone graft is used to replace the missing bone. The 
graft can be donor bone which has beeu frozen and 
stored, but infections are common with this method. 
Dr. Mark Cofone and Dr. David Diefenderfer have 
used autogenous, cancellous bone as the graft. Small 
amounts of the soft bone from the marrow cavity of 
the dog's own shoulder (proximal humerus), pelvis 
(ilium) or knee (proximal tibia) are used to replace 
the diseased bone. Plates and screws hold the bones 
in their proper orientation. It is complicated surgery 
and the time period until the bone graft has healed 
may be several months. Limb-sparing surgery is most 
successful for tumors of the distal radius (lower 
foreleg) because the carpal joint (wrist) can be fused 
without problems. 
Previously described chemorherapy treatment 
protocols for OSA incorporate cisptatin and/or 
adriamycin, usually given at three week intervals. 
The drugs are administered intravenously. They are 
both potent drugs that act on cell division. 
Adriamycin prevents DNA from replicating, thus 
slowing the growth of metastasized tumors. Cisplatin 
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Or. Joy Weinstein and one of her patienrs, a 
nine·year old Rottweiler who had his foreleg 
amputated. Cisplatin and adriamycin were 
administered perioperatively, followed by two 
additional treatments three weeks apart. Tbe dog is 
doing well and quite active. 
also affects the DNA, binding to it. crosslinking the 
strands. Both drugs affect other rapidly growing cells 
in the body, such as bone marrow cells and intestinal 
cells. Side effects are often minimal, but can include 
decreased appetite, gastrointestinal upset, bone 
marrow suppression, kidney problems, or heart 
problems. 
Dr. Weinstein proposes lO use the two drugs 
concurrently, administering therapeutic doses of 
cisplatin and slightly lower doses of adriamycin to 
fur1her slow down metastatic tumor growth. 
Preliminary studies have shown encouraging results, 
four dogs 1 rea ted are doing well six to ten months 
after Lreatment. She proposes to use the drugs 
postoperatively, beginning two weeks after surgery, 
in one group of patiems for a total of three cydes, 
three weeks apan. In another group of patients, the 
first dose of drugs wm be administered 
perioperatively, within 14 hours after surgery, 
followed by two additional treatments three weeks 
apart. "Studies in humans and rodents have shown 
that there is rapid growth of metastatic lesions in 
these species following surgical excision of primary 
tumors," she srud. "Studies in laboratory animal 
tumor models show that administration of 
peri operative chemotherapy prevents a rapid growth 
phase in metastatic lesions following removal of the 
primary tumor.'' Dr. Wdnstein explained that 
perioperative chemotherapy is not routinely 
administered t o  humans with the disease due to fear 
of postoperative surgical wound complications, such 
as infections and delayed wound healing. "Our 
previous results administering pre-, perioperative and 
postoperative adriamycin to dogs with osteosarcoma 
do not support high wound complication rates. We 
hope to document improved survival rates for 
patients treated with perioperative chemotheupy; 
this woul.d advance canine osteosarcoma treatment 
and might also encourage similar studies in human 
patients with the disease.'' 
Osteosarcoma in people is a d  isease of teenagers 
and young adults. In dogs it affects primarily 
middle-aged animaJs, though it does occur in dogs 
under two years of age and in elderly dogs. Canine 
osteosarcoma may serve as a model for human 
osteosarcoma and Dr. Weinstein is collaborating 
with researchers at the Medical SchooJ on several 
projects. "We are looking at MRL images of the 
amputated canine limb to establish how the tumor 
margins seen on the image correspond to the tumor 
margins established by histological examination." 
she explained. "lt is very difficult for the surgeon, 
when doing limb-sparing surgery on people or dogs, 
to know eJCact!y where the l umor ends," she said. 
"We hope to determine jusl how accurate the MRI 
scan is In defining the tumor margins." The studies 
also encompass a look at the role of growth factors 
and their receptors in canine osteosarcoma. The role 
of P-glycoprotein in the resistance of canine 
osteosarcoma to chemot,herapy will be investigated. 
The researchers hope to expand the project so that 
they can evaluate different clinical protocols in dogs 
with osteosarcoma and assess prognostic indicators 
and chemosensitivity assays to predict differences in 
the response to treatment. 
nr. Weinstein is currently searching for funding 
for the chemotherapy study from private sources or 
foundations to support the costs of the drugs. 
Without support, surgery and the chemotherapy 
drugs cost about $2,000 per patient. If support can be 
found, Lhese costs to the clients will decrease 
considerably. Dr. Weinstein is also looking for 
candidates for the treatment and she hopes that 
veterinarians with canine osteosarcoma patients will 
refer them to the Veterinary Hospital of the 
University of Pennsylvania. 
Dr. Weinstein graduated from the University of 
Pennsylvania School of Veterinary Medicine in 1983; 
she completed a surgery residency at Tufts University 
School of Veterinary Medicine and Angell Memorial 
Animal Hospital; and be.came an instructor in 
surgery at Tufts. She completed a research fellowship 
at Massachusetts Genefal Hospital where she worked 
in the laboratory of Dr. Henry Mankin. a pioneering 
researcher in bone cancer in people. 
Merck Supports 
Laboratory Animal 
Medicine Training 
Merck Sharp & Dohme Research Laboratories 
Djvision of Merck & Co., Inc. has provided a 
postdoctoral fellowship grant h1 Laboratory Animal 
Medicine at the Universi1y of Pennsylvania. Dr. 
Laurence Handt, a 1987 veterinary graduate of 
Mi�.:higan State University, has been selected as the 
first recipient of the grant and is now in the first year 
of the program. The laboratory animal medicine 
program has been in existence since 1987 at the 
University of Pennsylvania. It is a three-year 
program combining a residency in laboratory animal 
medicine with a master's degree in a related scientific 
discipline. Individuals enrolled in this program also 
complete a one-month rotation in c he Department of 
Laboratory Animal Resources at Merck's West 
Point, PA facility. This program is designed to 
develop competence in biomedical research and 
laboratory animal medicine, and prepare candidates 
for the American College of Laboratory Animal 
Medicine board certification. This joint effort of 
Merck and the University of Pennsylvania is an 
example of the growing trend of the business sector 
providing financial assistance to foster advanced 
training in scientific disciplines. 
Shown here (left to rigbt) are Dr. Harry Rozmiarek, 
director of t.he University of Pennsyl\'ania Office of 
University Laboratory Animal Resources and 
director ot the Laboratory Animal Medicine 
Training Program, Or. Jeffrey Linn, associate 
dirertor and clinical coordinator, Dr. L aurence 
Handt, Or. Gwendolyn McCormick, staff 
veterinarian with Merck's Department of Laboratory 
Animal Resources at West Point, PA and Dr. Hilton 
Klein, direc tor of Laboratory Animal Resources, 
MSORL Division of Merck. 
